Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Cyclosporine

FDA-approved product (injectable, injection), marketed as Cequa, Cyclosporine, Gengraf and 6 more.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Cyclosporine
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Conjunctivitis
  • Corneal disease
  • Eye disease
  • Immune system disease
  • Inflammation
  • Keratitis
  • Keratoconjunctivitis
  • Psoriasis
  • Rheumatoid arthritis

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Calcineurin inhibitors; Other ophthalmologicals
FDA pharmacologic class
Calcineurin Inhibitor Immunosuppressant FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli, MRSA, K. pneumoniae and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA61.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli53.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae56.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis50.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Cyclosporine in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Cyclosporine with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Antithymocyte Globulin and Cyclosporine to Treat Myelodysplasia

    NCT00005937 · start 2000-06

    Registered record
    Registry ID
    NCT00005937
    Conditions
    Myelodysplastic Syndrome
    Interventions
    Antithymocyte globulin; Cyclosporine
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2000-06
    Completion
    2008-03
    Enrolment
    42

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMyelodysplastic Syndrome
    InterventionAntithymocyte globulin; Cyclosporine
    PhasePhase 2
    Registry statusCompleted

  • Fludarabine and Cyclophosphamide in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Chronic Lymphocytic Leukemia or Waldenstrom's Macroglobulinemia

    NCT00281983 · start 2000-06

    Registered record
    Registry ID
    NCT00281983
    Conditions
    Chronic Lymphocytic Leukemia
    Interventions
    alemtuzumab; anti-thymocyte globulin; filgrastim; rituximab; therapeutic allogeneic lymphocytes; busulfan; cyclophosphamide; cyclosporine; fludarabine phosphate; methotrexate; mycophenolate mofetil; peripheral blood stem cell transplantation; radiation therapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2000-06
    Completion
    2010-07
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Lymphocytic Leukemia
    Interventionalemtuzumab; anti-thymocyte globulin; filgrastim; rituximab +9 more
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • Graft-Versus-Host Disease in Treating Patients With Recurrent or Refractory Lymphoma or Hodgkin's Disease

    NCT00003414 · start 1997-10

    Registered record
    Registry ID
    NCT00003414
    Conditions
    Graft Versus Host Disease; Lymphoma
    Interventions
    aldesleukin; recombinant interferon gamma; busulfan; cyclophosphamide; cyclosporine; peripheral blood stem cell transplantation; radiation therapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    1997-10
    Completion
    2004-05
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGraft Versus Host Disease; Lymphoma
    Interventionaldesleukin; recombinant interferon gamma; busulfan; cyclophosphamide +3 more
    PhasePhase 3
    Registry statusCompleted

  • Comparing Therapies for the Treatment of Severe Aplastic Anemia

    NCT00001626 · start 1997-06-02

    Registered record
    Registry ID
    NCT00001626
    Conditions
    Severe Aplastic Anemia (SAA)
    Interventions
    antithymocyte globulin; cyclophosphamide; cyclosporine
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    1997-06-02
    Completion
    2008-03-03
    Enrolment
    33

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSevere Aplastic Anemia (SAA)
    Interventionantithymocyte globulin; cyclophosphamide; cyclosporine
    PhasePhase 2
    Registry statusCompleted

  • Comparison of Biological Therapies Following Combination Chemotherapy and Bone Marrow or Peripheral Stem Cell Transplantation in Women With Stage II or Stage III Breast Cancer

    NCT00008203 · start 1996-05

    Registered record
    Registry ID
    NCT00008203
    Conditions
    Breast Cancer
    Interventions
    aldesleukin; recombinant interferon gamma; carboplatin; cyclophosphamide; cyclosporine; thiotepa; autologous bone marrow transplantation; peripheral blood stem cell transplantation
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    1996-05
    Completion
    2008-05
    Enrolment
    Not recorded

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Cancer
    Interventionaldesleukin; recombinant interferon gamma; carboplatin; cyclophosphamide +4 more
    PhasePhase 3
    Registry statusCompleted